Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients The recent adoption of PET scanning for management decisions is an area of essential audit and in this excellent study authored by Marta Zafra et al.from Spain, Volume 44:12 Pages 1678-1683, data is presented in all patients who received PET scanning for a 12 month period. The results show that diagnosis was modified in 63% of patients and management in 34% of cases. This is very timely evidence-based data to assess the value of PET scanning. Click here to view paper Expression profiling of angiogenic genes for the characterisation of colorectal carcinoma In this study by Alessandro Carrer et al from Italy, Volume 44:12 Pages 1761-1769, the expression levels of angiogenic and angiostatic factors were determined in paired, normal and tumour samples of patients with colorectal carcinoma and correlated with clinical outcome. This paper adds useful data to the concept that expression levels of selected genesinvolved in angiogenesis represent trustable biomarkers of tumour development and invasion. Click here to view paper Increased alternative splicing of the KLF6 tumour suppressor gene correlates with the prognosis and tumour grade in patients with pancreatic cancer Pancreatic cancer remains one of the most devastating of the malignant diseases and any advances in our understanding of the biology of this very difficult cancer are to be welcomed. Published in Volume 44:13 Pages 1895-1903, this study by Market Hartel et al, Heidelberg, Munich and New York, aimed to correlate the status of the KLF6 tumour suppressor gene using loss of heterozygosity, mutation and alternative splicing in human pancreatic cancers, in comparison with tumour grade and survival. The data show a novel pattern of KLF6 disregulation in pancreatic cancer and the authors suggest that this may represent a novel biomarker of use in predicting prognosis. Click here to view paper Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies There is great interest in the new range of molecules that have activity in renal cell cancer and in this excellent and timely review from Simon Chowdhury et al at the Royal Marsden Hospital in London, the data on Sunitinib, Sorafenib, temsirolimus and bevacizumab are reviewed in comparison with previously established immunotherapy using interferon-alpha. It is particularly appropriate that this review published in Volume 44: 15 Pages 2152-2161 comes from London where the English authorities have recently made controversial decisions on the availability of these new agents for renal cell carcinoma. Click here to view paper
The recent adoption of PET scanning for management decisions is an area of essential audit and in this excellent study authored by Marta Zafra et al.from Spain, Volume 44:12 Pages 1678-1683, data is presented in all patients who received PET scanning for a 12 month period.
The results show that diagnosis was modified in 63% of patients and management in 34% of cases. This is very timely evidence-based data to assess the value of PET scanning.
Click here to view paper
Expression profiling of angiogenic genes for the characterisation of colorectal carcinoma
In this study by Alessandro Carrer et al from Italy, Volume 44:12 Pages 1761-1769, the expression levels of angiogenic and angiostatic factors were determined in paired, normal and tumour samples of patients with colorectal carcinoma and correlated with clinical outcome.
This paper adds useful data to the concept that expression levels of selected genes
involved in angiogenesis represent trustable biomarkers of tumour development and invasion.
Increased alternative splicing of the KLF6 tumour suppressor gene correlates with the prognosis and tumour grade in patients with pancreatic cancer
Pancreatic cancer remains one of the most devastating of the malignant diseases and any advances in our understanding of the biology of this very difficult cancer are to be welcomed.
Published in Volume 44:13 Pages 1895-1903, this study by Market Hartel et al, Heidelberg, Munich and New York, aimed to correlate the status of the KLF6 tumour suppressor gene using loss of heterozygosity, mutation and alternative splicing in human pancreatic cancers, in comparison with tumour grade and survival.
The data show a novel pattern of KLF6 disregulation in pancreatic cancer and the authors suggest that this may represent a novel biomarker of use in predicting prognosis.
There is great interest in the new range of molecules that have activity in renal cell cancer and in this excellent and timely review from Simon Chowdhury et al at the Royal Marsden Hospital in London, the data on Sunitinib, Sorafenib, temsirolimus and bevacizumab are reviewed in comparison with previously established immunotherapy using interferon-alpha.
It is particularly appropriate that this review published in Volume 44: 15 Pages 2152-2161 comes from London where the English authorities have recently made controversial decisions on the availability of these new agents for renal cell carcinoma.